BRIEF-Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study

Reuters

06-24

BRIEF-Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study

June 24 (Reuters) - Veru Inc VERU.O:

VERU REPORTS POSITIVE RESULTS FROM PHASE 2B QUALITY AND MAINTENANCE EXTENSION STUDY SHOWING ENOBOSARM SIGNIFICANTLY REDUCED BODY WEIGHT REGAIN, PREVENTED FAT REGAIN, AND PRESERVED LEAN MASS AFTER SEMAGLUTIDE DISCONTINUATION
VERU INC - ENOBOSARM 3MG REDUCES WEIGHT REGAIN BY 46% AFTER SEMAGLUTIDE DISCONTINUATION
VERU INC - ENOBOSARM SHOWS 93% GREATER FAT LOSS, 100% LEAN MASS PRESERVATION
VERU INC - ENOBOSARM MONOTHERAPY SHOWS POSITIVE SAFETY PROFILE WITH NO GI SIDE EFFECTS
VERU INC - GRANTED FDA MEETING TO DISCUSS PHASE 3 CLINICAL PROGRAM
VERU INC - ENOBOSARM 3MG TO ADVANCE AS PROPOSED DOSE FOR PHASE 3 CLINICAL PROGRAM

Source text: ID:nGNXbbvp7V

Further company coverage: VERU.O

((Reuters.Briefs@thomsonreuters.com;))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2545287880"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2545287880\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2545287880?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-24 20:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545287880","market":"nz","top_or_hot":-1,"title":"BRIEF-Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study </title></head><body><p><span>June 24 (Reuters)</span><span> - </span>Veru Inc <span>VERU.O</span>:</p><ul><li><p>VERU REPORTS POSITIVE RESULTS FROM PHASE 2B QUALITY AND MAINTENANCE EXTENSION STUDY SHOWING ENOBOSARM SIGNIFICANTLY REDUCED BODY WEIGHT REGAIN, PREVENTED FAT REGAIN, AND PRESERVED LEAN MASS AFTER SEMAGLUTIDE DISCONTINUATION</p></li><li><p>VERU INC - ENOBOSARM 3MG REDUCES WEIGHT REGAIN BY 46% AFTER SEMAGLUTIDE DISCONTINUATION</p></li><li><p>VERU INC - ENOBOSARM SHOWS 93% GREATER FAT LOSS, 100% LEAN MASS PRESERVATION</p></li><li><p>VERU INC - ENOBOSARM MONOTHERAPY SHOWS POSITIVE SAFETY PROFILE WITH NO GI SIDE EFFECTS</p></li><li><p>VERU INC - GRANTED FDA MEETING TO DISCUSS PHASE 3 CLINICAL PROGRAM</p></li><li><p>VERU INC - ENOBOSARM 3MG TO ADVANCE AS PROPOSED DOSE FOR PHASE 3 CLINICAL PROGRAM</p></li></ul><p>Source text: <span>ID:nGNXbbvp7V</span></p><p>Further company coverage: <span>VERU.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-24 20:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study </title></head><body><p><span>June 24 (Reuters)</span><span> - </span>Veru Inc <span>VERU.O</span>:</p><ul><li><p>VERU REPORTS POSITIVE RESULTS FROM PHASE 2B QUALITY AND MAINTENANCE EXTENSION STUDY SHOWING ENOBOSARM SIGNIFICANTLY REDUCED BODY WEIGHT REGAIN, PREVENTED FAT REGAIN, AND PRESERVED LEAN MASS AFTER SEMAGLUTIDE DISCONTINUATION</p></li><li><p>VERU INC - ENOBOSARM 3MG REDUCES WEIGHT REGAIN BY 46% AFTER SEMAGLUTIDE DISCONTINUATION</p></li><li><p>VERU INC - ENOBOSARM SHOWS 93% GREATER FAT LOSS, 100% LEAN MASS PRESERVATION</p></li><li><p>VERU INC - ENOBOSARM MONOTHERAPY SHOWS POSITIVE SAFETY PROFILE WITH NO GI SIDE EFFECTS</p></li><li><p>VERU INC - GRANTED FDA MEETING TO DISCUSS PHASE 3 CLINICAL PROGRAM</p></li><li><p>VERU INC - ENOBOSARM 3MG TO ADVANCE AS PROPOSED DOSE FOR PHASE 3 CLINICAL PROGRAM</p></li></ul><p>Source text: <span>ID:nGNXbbvp7V</span></p><p>Further company coverage: <span>VERU.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nTUABDGWZB:1","article_id":"2545287880","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545287880","pubTimestamp":1750768565,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study June 24 (Reuters) - Veru Inc VERU.O:VERU REPORTS POSITIVE RESULTS FROM PHASE 2B QUALITY AND MAINTENANCE EXTENS","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4584":"避孕概念","BK4183":"个人用品","BK4557":"大麻股","VERU":"Veru Inc."},"translate_title":"BRIEF-Veru报告2b期质量和维护扩展研究的积极结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VERU":0.9},"content_text":"BRIEF-Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study June 24 (Reuters) - Veru Inc VERU.O:VERU REPORTS POSITIVE RESULTS FROM PHASE 2B QUALITY AND MAINTENANCE EXTENSION STUDY SHOWING ENOBOSARM SIGNIFICANTLY REDUCED BODY WEIGHT REGAIN, PREVENTED FAT REGAIN, AND PRESERVED LEAN MASS AFTER SEMAGLUTIDE DISCONTINUATIONVERU INC - ENOBOSARM 3MG REDUCES WEIGHT REGAIN BY 46% AFTER SEMAGLUTIDE DISCONTINUATIONVERU INC - ENOBOSARM SHOWS 93% GREATER FAT LOSS, 100% LEAN MASS PRESERVATIONVERU INC - ENOBOSARM MONOTHERAPY SHOWS POSITIVE SAFETY PROFILE WITH NO GI SIDE EFFECTSVERU INC - GRANTED FDA MEETING TO DISCUSS PHASE 3 CLINICAL PROGRAMVERU INC - ENOBOSARM 3MG TO ADVANCE AS PROPOSED DOSE FOR PHASE 3 CLINICAL PROGRAMSource text: ID:nGNXbbvp7VFurther company coverage: VERU.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}